Redefining Pediatric
Vitamin D3 Outcomes
A strategic proposal to generate Real-World Evidence (RWE) validating the superior absorption and clinical effectiveness of Kidrich-D3 Nano Drops in the Indian pediatric population.
The Challenge
Despite abundant sunshine, Vitamin D deficiency remains pervasive. Conventional oil-based formulations often suffer from variable bioavailability, leading to slow recovery in rickets and impaired immunity.
The Innovation
Kidrich-D3 leverages cutting-edge Nano-emulsion technology. By reducing particle size, we bypass physiological barriers to significantly enhance cholecalciferol solubility and speed of action.
The Strategy
Bridge the evidence gap with a robust prospective study. We aim to move beyond theoretical advantages and provide clinical proof of Kidrich-D3's superiority over market-leading conventional brands.
Phase 1: Market Defense Queries (90 Days)
The 'Happy Baby' Study
N=500 Mother reported outcome survey on gastric tolerability.
Switch Success Cases
Clinical documentation of refractory cases solved by Kidrich.
Phase 2: Strategic Portfolio (Supporting Data)
Comparative Study
Mean absolute increase in Serum 25(OH)D levels from Baseline (Day 0) to Week 12.
Bioavailability
Head-to-head absorption data.
Long-term Safety
12-month AE monitoring.
Cost-Effectiveness
Value dossier modeling.
Physician Drivers
Prescription behavior study.